358 related articles for article (PubMed ID: 18713995)
21. Analysis of FOXP3
Schmidt A; Rieger CC; Venigalla RK; Éliás S; Max R; Lorenz HM; Gröne HJ; Krammer PH; Kuhn A
Immunol Res; 2017 Apr; 65(2):551-563. PubMed ID: 28224362
[TBL] [Abstract][Full Text] [Related]
22. Cellular and Molecular Phenotypes of pConsensus Peptide (pCons) Induced CD8
Singh RP; Hahn BH; Bischoff DS
Front Immunol; 2021; 12():718359. PubMed ID: 34867947
[TBL] [Abstract][Full Text] [Related]
23. Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease.
Wong M; La Cava A; Singh RP; Hahn BH
J Immunol; 2010 Dec; 185(11):6563-71. PubMed ID: 21041733
[TBL] [Abstract][Full Text] [Related]
24. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus.
Parameswaran R; Ben David H; Sharabi A; Zinger H; Mozes E
Clin Immunol; 2009 May; 131(2):223-32. PubMed ID: 19188092
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus.
Zhang B; Zhang X; Tang FL; Zhu LP; Liu Y; Lipsky PE
Ann Rheum Dis; 2008 Jul; 67(7):1037-40. PubMed ID: 18199598
[TBL] [Abstract][Full Text] [Related]
26. Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells.
Scalapino KJ; Daikh DI
PLoS One; 2009 Jun; 4(6):e6031. PubMed ID: 19551149
[TBL] [Abstract][Full Text] [Related]
27. Mouse IL-2/CD25 Fusion Protein Induces Regulatory T Cell Expansion and Immune Suppression in Preclinical Models of Systemic Lupus Erythematosus.
Xie JH; Zhang Y; Loubeau M; Mangan P; Heimrich E; Tovar C; Zhou X; Madia P; Doyle M; Dudhgaonkar S; Rudra A; Subramani S; Young J; Salter-Cid L; Malek TR; Struthers M
J Immunol; 2021 Jul; 207(1):34-43. PubMed ID: 34108258
[TBL] [Abstract][Full Text] [Related]
28. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
[TBL] [Abstract][Full Text] [Related]
30. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets.
Kang HK; Michaels MA; Berner BR; Datta SK
J Immunol; 2005 Mar; 174(6):3247-55. PubMed ID: 15749855
[TBL] [Abstract][Full Text] [Related]
31. Requirement of CD28 signaling in homeostasis/survival of TGF-beta converted CD4+CD25+ Tregs from thymic CD4+CD25- single positive T cells.
Liu Y; Amarnath S; Chen W
Transplantation; 2006 Oct; 82(7):953-64. PubMed ID: 17038912
[TBL] [Abstract][Full Text] [Related]
32. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.
Valencia X; Yarboro C; Illei G; Lipsky PE
J Immunol; 2007 Feb; 178(4):2579-88. PubMed ID: 17277168
[TBL] [Abstract][Full Text] [Related]
33. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors.
Hahn BH; Singh RP; La Cava A; Ebling FM
J Immunol; 2005 Dec; 175(11):7728-37. PubMed ID: 16301683
[TBL] [Abstract][Full Text] [Related]
34. Increased CD4
Yin ZJ; Ju BM; Zhu L; Hu N; Luo J; He M; Feng XY; Lv XH; Pu D; He L
Lupus; 2018 Nov; 27(13):2057-2068. PubMed ID: 30336752
[TBL] [Abstract][Full Text] [Related]
35. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells.
Huang H; Dawicki W; Zhang X; Town J; Gordon JR
J Immunol; 2010 Nov; 185(9):5003-10. PubMed ID: 20870943
[TBL] [Abstract][Full Text] [Related]
36. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
[TBL] [Abstract][Full Text] [Related]
37. Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β.
Horwitz DA; Bickerton S; Koss M; Fahmy TM; La Cava A
Arthritis Rheumatol; 2019 Apr; 71(4):632-640. PubMed ID: 30407752
[TBL] [Abstract][Full Text] [Related]
38. A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide.
Lapter S; Ben-David H; Sharabi A; Zinger H; Telerman A; Gordin M; Leng L; Bucala R; Shachar I; Mozes E
Immunology; 2011 Jan; 132(1):87-95. PubMed ID: 20738420
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of stromal cell-derived factor-1alpha-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-beta secretion.
Sela U; Hershkoviz R; Cahalon L; Lider O; Mozes E
J Immunol; 2005 Jan; 174(1):302-9. PubMed ID: 15611253
[TBL] [Abstract][Full Text] [Related]
40. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.
Ben-David H; Sharabi A; Parameswaran R; Zinger H; Mozes E
Immunology; 2009 Oct; 128(2):245-52. PubMed ID: 19740381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
